OutSee has secured £1.8 ($2.4) million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures. The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the company’s in-house… Read More
Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has collaborated with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational… Read More
Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting. This is RBL’s first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for… Read More
University of Michigan (U-M) spinout company Courage Therapeutics has received a seed investment of up to $7.8 million from Arsenal Bridge Ventures. The investment will enable Courage Therapeutics to complete essential testing and development to advance its drug candidates to clinical trials. The company’s two… Read More
A drug discovery company co-founded by researchers at the University of Dundee and the University of Arizona has received $4 million in venture funding. Branch Therapeutics, founded in November 2024, is a preclinical stage company seeking to develop drugs that are orally bioavailable, well-tolerated, and can treat… Read More
Enedra Therapeutics has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers. The financing round was supported by KU Leuven’s Centre for Drug Design and Discovery (CD3), o2h… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting… Read More
Basel Area Business & Innovation has relaunched its DayOne Accelerator, a programme dedicated to international early stage healthtech ventures looking to engage with the pharma industry. The Accelerator is based in Basel, Switzerland – a leading life sciences hub, home to pharma giants like Novartis and Roche. … Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are… Read More
A new start-up aimed at discovering and developing anti-inflammatory disease medicines has been formed by The University of Queensland’s commercialisation arm UniQuest and global biotech company Molecule to Medicine (MTM). Curlew Bio will leverage expertise from the Queensland Emory and Drug Discovery Initiative (QEDDI) and research developed… Read More
News round-up for 3-7 March by DDW Senior Digital Content Editor Diana Spencer. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are coming through and sparking new life into various areas of drug discovery. The top stories: Start-up… Read More
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, has closed a $31 million seed funding round. The investment will support further development of the company’s pipeline of central nervous system (CNS) penetrant therapeutics based on its aggregate-selective degrader molecules… Read More
Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round. Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. The newly formed company, with headquarters in Seattle and Singapore,… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where are the global epicentres of drug discovery innovation?”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Where are the hottest drug discovery hubs in the… Read More
DDW Editor Reece Armstrong speaks to Dr Carina Kern, Chief Executive Officer and Chief Scientific Officer, and Serena Kern-Libera, Chief Operating Officer, at LinkGevity about the company’s approach to tackling age-related diseases. RA: Could you tell us about LinkGevity’s approach to developing broad-spectrum therapeutics in the field of ageing? … Read More
Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics. The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds. … Read More
